References
- Banikarim C, Chacko M R, Kelder S H. Prevalence and impact of dysmenorrhoea on Hispanic female adolescents. Archives of Paediatric and Adolescent Medicine 2000; 154: 1226–1229
- Chan W Y, Hill J C. Determination of menstrual prostaglandin levels in nondysmenorrhoea and dysmenorrhoea subjects. Prostaglandins 1978; 15: 365
- Davis A R, Westhoff C L. Primary dysmenorrhoea in adolescent girls and treatment with oral contraceptives. Journal of Pediatric and Adolescent Gynecology 2001; 14: 3–8
- Dawood M Y, Khan-Dawood F S. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2 in a randomized, double blind, crossover treatment with placebo, acetaminophen and ibuprofen in primary dysmenorrhoea. American Journal of Obstetrics and Gynecology 2007a; 196: 35.e1–35.e5
- Dawood M Y, Khan-Dawood F S. Differential suppression of menstrual fluid prostaglandin F2a, prostaglandin E2, 6-keto Prostaglandin F1a and thromboxane B2 by suprofen in women with primary dysmenorrhoea. Prostaglandins and Other Lipid Mediators 2007b; 83: 146–153
- French L. Dysmenorrhoea. American Family Physician 2005; 71: 285–291
- Harel Z. Dysmenorrhoea in adolescent and young adults. Journal of Pediatric and Adolescent Gynecology 2006; 19: 363–371
- Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhoea. Journal of Adolescent Health 1988; 9: 398
- Klein J R, Litt I F. Epidemiology of adolescent dysmenorrhoea. Paediatrics 1981; 68: 661
- Lee L K, Chen P C, Lee K K, Kaur J. Menstruation among adolescent girls in Malaysia: a cross-sectional school survey. Singapore Medical Journal 2006; 47: 869
- Lundstrom V, Green K. Endogenous levels of prostaglandin F2α and its main metabolites in plasma and endometrium of normal and dysmenorrheic woman. American Journal of Obstetrics and Gynaecology 1978; 130: 640
- Malmstrom K, Kotey P, Cichanowitz N, Daniels S, Desjardins P J. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecologic and Obstetric Investigation 2003; 56: 65–69
- Milsom I, Minic M, Dawood M Y, Akin M D, Spann J, Niland N F, et al. Comparison of the efficacy and safety of nonprescription doses of Naproxen and Naproxen Sodium with Ibuprofen, Acetaminophen and placebo in the treatment of primary dysmenorrhoea: A pooled analysis of five studies. Clinical Therapeutics 2002; 24: 1384–1400
- Nirawanti M S, Nazrah Z H, Najwa H M, Nor Shazatul S D, Nor Azlin M I, Zainul Rashid M R. Dysmenorrhoea in our community: Grimace to dignity?. International Medical Journal 2006; 5: 2, Available at: http://www.e-imj.com/Vol5-No2/Vol5-No2-B2.htm
- Simopoulos A. Omega-3 fatty acids in health and disease and in growth and development. American Journal of Clinical Nutrition 1991; 54: 438
- Raine-Fenning. Dysmenorrhoea. Current Obstetrics and Gynaecology 2005; 15: 394–401
- Rees M C, DiMarzo V, Tippins J R, Morris H R, Turnbull A C. Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia. Journal of Endocrinology 1987; 113: 291
- Roy S. A double-blind comparison of a propionic acid derivatives (Ibuprofen) and a fenamate (mefenamic acid) in the treatment of dysmenorrhoea. Obstetrics and Gynecology 1983; 62: 628
- Twigg J. Dysmenorrhoea. Current Obstetrics and Gynaecology 2002; 12: 341–345